千金药业(600479.SH)：药品恩格列净片获得药品注册证书

Core Insights - Qianjin Pharmaceutical (600479.SH) has received the drug registration certificate for Empagliflozin tablets (10mg, 25mg) from the National Medical Products Administration [1] - Empagliflozin is an oral, once-daily, highly selective sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption and promotes glucose excretion through urine, thereby lowering blood sugar levels [1] - The drug has a unique mechanism of action that does not rely on insulin and provides additional cardiovascular and renal protective effects [1] - As of the announcement date, Qianjin Xiangjiang Pharmaceutical has invested a total of RMB 4.454 million in the research and development of Empagliflozin tablets [1]